Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs


Arcturus Therapeutics Holdings Inc ARCT announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying mRNA vaccine candidates for COVID-19.

  • ARCT-154 and ARCT-165 are being studied in a Phase 1/2 trial in U.S. and Singapore. 
  • The study evaluates Arcturus' COVID vaccine candidates as both a primary vaccination series and a booster following initial vaccination with Pfizer Inc PFEBioNTech SE's BNTX Comirnaty. 
  • Preliminary immunogenicity results from the first eight of 12 ARCT-154 administered participants, and the first nine of 12 participants with ARCT-165 as a booster demonstrates an encouraging increase in neutralizing antibody titers.
  • Additional data shows activity against several variants of concern and variants of interest upon boosting with ARCT-154 (5 mcg) and ARCT-165 (5 mcg).
  • ARCT-154 is also being studied in an ongoing pivotal trial in Vietnam, sponsored and funded by Arcturus' collaborator Vinbiotech.
  • The Company anticipates submitting regulatory documents in Vietnam this month, completing the Emergency Use Authorization application in Q1 of 2022, assuming positive data.
  • Arcturus also plans to evaluate sera from ARCT-154, and ARCT-165 vaccinated participants against the omicron variant and expects preliminary data in Q1 of 2022.
  • Price Action: ARCT shares are up 19.20% at $42.34 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLong IdeasNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 VaccinePhase 1 TrialPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!